key: cord-0077551-x4tqqhky
authors: Zhang, Yufei; Gao, Jindong; Huang, Kun; Zhao, Ya; Hui, Xianfeng; Wang, Ting; Hu, Changmin; Sun, Xiaomei; Yang, Ying; Wu, Chao; Chen, Xi; Zou, Zhong; Zhao, Lian zong; Jin, Meilin
title: SARS-CoV-2 infection causes hyperglycaemia in cats
date: 2022-04-20
journal: J Infect Dis
DOI: 10.1093/infdis/jiac143
sha: d7c049ce63996512e68b216e8c4e6d8ed1eed838
doc_id: 77551
cord_uid: x4tqqhky

Isolated reports of new-onset diabetes in patients with COVID-19 have led researchers to hypothesise that SARS-CoV-2 infects the human exocrine and endocrine pancreatic cells ex vivo and in vivo. However, existing research lacks experimental evidence indicating that SARS-CoV-2 can infect pancreatic tissue. Here, we found that cats infected with a high dose of SARS-CoV-2 exhibited hyperglycaemia. We also detected SARS-CoV-2 RNA in the pancreatic tissues of these cats, and immunohistochemical staining revealed the presence of SARS-CoV-2 nucleocapsid protein (NP) in the islet cells. SARS-CoV-2 NP and Spike proteins were primarily detected in Glu+ cells, and most Glu+ cells expressed ACE2. Additionally, immune protection experiments conducted on cats showed that the blood glucose levels of immunised cats did not increase post-challenge. Our data indicate the cat pancreas as a SARS-CoV-2 target and suggest that the infection of Glu+ cells could contribute to the metabolic dysregulation observed in SARS-CoV-2-infected cats.

Coronavirus disease 19 (COVID-19), caused by a severe acute respiratory syndrome 2 coronavirus 2 (SARS-CoV-2) infection, has been declared a pandemic and continues to 3 present a serious threat to public health worldwide. As of March 2021, 458,479,635 cases 4 of COVID-19 were confirmed, and 6,047,653 patients had succumbed to the disease 5 globally. The number of cases and deaths continues to rise, and a second wave of 6 infection has been reported in certain countries that had reopened their economies. 7 Moreover, the emergence of SARS-CoV-2 variants with enhanced transmissibility, 8 pathogenesis, and resistance to vaccines presents an urgent challenge to best control the 9 COVID-19 pandemic [1] [2] [3] [4] . Reports published to date on the COVID-19 outbreak include 10 a large quantity of data indicating the presence of a bidirectional interaction between 11 COVID-19 and diabetes. However, the mechanisms underlying this interaction remain 12 elusive [5] [6] [7] [8] [9] [10] [11] [12] . Multiple forms of diabetes, including new-onset diabetes, and metabolic 13 complications, such as diabetic ketoacidosis and hyperosmolarity, might be observed in 14 patients with COVID-19 [6] [7] [8] [9] [10] [11] [12] . Intriguingly, emerging evidence shows that a new 15 diagnosis of diabetes is frequently observed in patients with COVID-19 and is a risk 16 factor for poor prognosis, particularly in patients with severe to critical COVID-19 [6- 17 12] . Therefore, fasting blood glucose (FBG) is an important prognostic factor in COVID- 18 19, which can be used to estimate the magnitude of association between COVID-19 and 19 diabetes. While a J-shaped association between FBG content and COVID-19 severity has 20 been reported in patients without diabetes [12] , the molecular mechanism underlying the 21 A C C E P T E D M A N U S C R I P T 4 relationship between COVID-19 and hyperglycemia remains unclear. 1 The precise mechanisms underpinning the development of new-onset diabetes in patients 2 with COVID-19 remain unknown, but it is likely that a number of complex, interrelated 3 etiologies are responsible, including impairments in both glucose disposal and insulin 4 secretion, stress hyperglycemia, preadmission diabetes, and steroid-induced diabetes [13, 5 14] . Previous data have demonstrated that SARS-CoV-2 triggers transient hyperglycemia 6 and impaired pancreatic β-cell function in the context of epidemic-derived pneumonia 7 [15] [16] [17] [18] . However, evidence of ACE2 expression in pancreatic cells remains conflicting, 8 with studies pointing to ACE2 expression in a limited subset of β-cells [19]. 9 Alternatively, the proinflammatory cytokines and acute-phase reactants resulting from 10 COVID-19 could directly result in inflammation and damage to pancreatic β-cells [13] . 11 Moreover, the COVID-19-induced inflammation and cytokine storm (CS), which are 12 characterized by profound increases in the levels of tumor necrosis factor-alpha (TNF-α) 13 and interleukin (IL)-6, lead to peripheral insulin resistance (IR). Another study has 14 revealed that adipose dysfunction is a feature of COVID-19 that may drive 15 hyperglycemia [20] . Taken together, data suggest that IR, adipose dysfunction, and 16 impairment of pancreatic β-cell function contribute to a vicious cycle involved in the 17 development and progression of hyperglycemia in COVID-19 patients [21] . However, the 18 current study cannot address in detail the mechanisms underpinning islet impairment and 19 metabolic dysregulation. Further cellular and animal models need to be analyzed to 20 address this question. 21 A C C E P T E D M A N U S C R I P T 1 could transmit the virus, and dogs showed low susceptibility [22] [23] [24] [25] [26] [27] . Here, we present an 2 in-depth study of SARS-CoV-2-infection-associated disease in domestic cats. 3 Interestingly, in this study, an unexpected and abnormal increase in blood glucose levels 4 was observed in cats with SARS-CoV-2 infection under laboratory conditions. 5 Meanwhile, SARS-CoV-2 RNA and protein were detected in the pancreas of these cats. 6 In addition, we also observed the cellular localization pattern of SARS-CoV-2 in 7 pancreatic endocrine cells and explored an effective animal model for the thorough 8 investigation of the pathogenic mechanism underlying SARS-CoV-2 infection in patients 9 with new-onset diabetes. 10 12 SARS-CoV-2 (strain HB-01) was kindly provided by Professor Zheng-Li Shi from the 13 Wuhan Institute of Virology, Chinese Academy of Sciences3,19. Vero E6 cells (ATCC ® 14 CRL-1586™), used for the reproduction of SARS-CoV-2 stocks, were cultured in 15 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine 16 serum (FBS) and antibiotics (100 U/mL penicillin/streptomycin), and incubated at 37 ºC 17 in an atmosphere with 5% CO 2 . The virus was titrated using 10-fold serial dilutions in 18 Vero E6 cells. Three days after the inoculation, the cytopathic effect (CPE) was scored, 19 and the Reed-Muench formula was used to calculate the TCID 50 value. All experiments 20 involving SARS-CoV-2 were performed at a Biosafety Level-3 (BSL3) containment were acclimated for seven days to the BSL3 animal facility prior to experimental 8 procedures with feed and water ad libitum. Before infection, the animals were examined 9 clinically, determined to be healthy by a registered veterinarian, and placed in negative 10 pressure glove boxes. 11 To assess the replication of SARS-CoV-2, nine close relatives of the specific-pathogen- 12 free cats (70-100 days) were housed in individual biosafety isolators and divided into 13 four groups. A total of two animals from each group were assigned to three subgroups: A, 14 B, and C. These groups were inoculated with 2 mL of virus solution containing 2 × 10 7 15 TCID 50 of HB-01 isolates, respectively, with 1 mL administered intratracheally and 1 mL 16 administered intranasally. Three control cats in group D were mock-infected in an 17 identical manner with 2 mL of Vero E6 cell culture supernatant. The animals were 18 monitored daily for clinical signs. At 3, 5, and 7 dpi, the cats were euthanised by arterial 19 whole blood sampling under Dexmedetomidine 5 μg/kg and ketamine 4 mg/kg IM 20 anaesthesia. Take 0.5 mL intramuscular injection according to the volume of 1:1 mixture, 21 A C C E P T E D M A N U S C R I P T 7 achieve irreversible deep anesthesia beyond the surgical period. The technique of carotid 1 artery cannulation has been described previously [29] [30] [31] . Briefly, after heparinization, 2 the ventral aspect of the neck was clipped and prepared for surgery. The right carotid 3 artery was surgically exposed. A 10F straight arterial cannula was placed retrograde in the 4 carotid artery. Heparin (400U/kg) was administered to increase activated clotting time 5 (ACT) to >480 seconds. Arterial return blood was collected after releasing the clamps on 6 the venous and arterial lines. The animals were necropsied according to a standard protocol involving opening of the 9 thoracic and abdominal cavities and the skull and examination of all major organs, 10 including the brain. Two animals from each group were sacrificed at 3, 5, and 7 dpi, and 11 the lungs, spleen, lymph nodes, small intestine, kidney, trachea, cerebrum, pancreas, sex 12 glands, stomach, and heart were harvested from each animal. The tissues were fixed in Challenge assay in cats 20 Nine cats were used for evaluating the toxicity and immunogenicity of the inactivation

viruses. Alum, a common adjuvant, was administered at 0.45 mg/dose for animal 1 immunisation, and the alum-buffer served as the negative control. All cats were 2 immunised at days 0, 14. A challenge study was conducted 24 days after the second 3 round of immunisation by directly inoculating 2 mL of 10 7 TCID 50 of SARS-CoV-2 (1 4 mL administered intratracheally and 1 mL administered intranasally). Cats were observed 5 daily for clinical signs, such as: fever, anorexia, lethargy, respiratory distress, 6 inappetence, coughing, sneezing, diarrhea and vomiting. These general symptoms in the 7 animals were monitored and recorded each day during the experiment. Blood and serum 8 were collected from all cats, on days 3-, 5-and 7-day post challenge (DPC) via arterial 9 catheterization of the carotid artery under anesthesia. Euthanasia was carried out as 10 described above. A full postmortem examination was performed for each cat at the 11 indicated time-points and gross changes (if any) were recorded. Tissues were collected 12 either in 10% neutral-buffered formalin, and as fresh tissues which were used to measure 13 the viral load. Fresh frozen tissue homogenates were prepared by thawing frozen tissue 14 and placing 200 mg (± 50 mg) of minced tissue in a tube containing 1 mL DMEM 15 culture medium and a steel bead (Hubei Xinzongke viral Disease Control Bio-Tech). 

To assess the replication and pathogenicity of SARS-CoV-2 in cats, nine cats (70-100- 9 day old) were divided into the infection and control groups. The cats in the infection 10 group were inoculated with 2 mL of a solution containing the HB-01 strain at 2 × 10 7 11 median tissue culture infectious dose (TCID 50 )/mL, with 1 mL administered 12 intratracheally and 1 mL administered intranasally ( Figure 1A ). The cats in the control 13 group were mock infected with 2 mL of Vero E6 cell culture supernatant following the Figure 1B) . Notably, the pancreatic tissues of all infected 2 cats tested positive for viral RNA at 5 and 7 dpi ( Figure 1B) , whereas the liver, spleen, 3 kidney, testis, and heart tissues did not ( Figure 1B ). In addition, viral titer measurement 4 indicated that the infectious viruses proliferated in the turbinates, tracheae, and lung 5 tissues but not in the small intestine, pancreas, heart, liver, spleen, kidneys, brain, and 6 submaxillary lymph nodes (Supplementary Figure S2) . 7 Based on the viral RNA expression in the pancreatic tissues of all infected cats at 5 and 7 8 dpi, we hypothesized that the pancreas represented a potential target organ affected by 9 SARS-CoV-2 infection. The pancreas is a critical organ that controls the blood glucose 10 content. To assess whether SARS-CoV-2 could influence glucose metabolism, we 11 measured the blood glucose concentration of the cats before and after viral inoculation. 12 We observed that almost all SARS-CoV-2-infected cats exhibited hyperglycemia (except 13 cats #7-1, SARS-CoV-2-infected a cat at 7 dpi), whereas the cats in the control group did 14 not exhibit hyperglycemia ( Figure 1C ). This indicated a positive correlation between Figure 1E ). As expected, the SARS-CoV-2 NP was detected in the 1 turbinates, soft palates, tracheae, bronchioles, and alveolar epithelial cells of the infected 2 cats (Supplementary Figure S3A) . However, it was not detected in the liver, kidney, and 3 brain tissue samples (Supplementary Figure S3D) . Figure S4A ). The above results strongly suggest that SARS-CoV-2 can invade the islet 8 cells and pancreatic ductal epithelial cells of cats. 9 The mechanism of virus entry is not completely clear at this point, as expression patterns 10 of the SARS-CoV-2 entry gene ACE2 in the cells of the cat endocrine and exocrine 11 pancreas remain unknown. Therefore, we performed immunohistochemical triple staining 12 for the viral N protein, glucagon, and insulin, and observed a high number of viral NP-13 glucagon double-positive cells but only a few viral NP-insulin double-positive cells 14 ( Figure 2A1-4) . Likewise, similar results were identified when spike protein-specific 15 antibodies were used ( Figure 2B1-4) . Additionally, we performed immunohistochemical 16 triple staining for viral NP, glucagon, and ACE2, and observed a high number of triple-17 positive cells ( Figure 2C1-4) . Pancreatic tissue isolated from uninfected cats did not show 18 immunopositivity for SARS-CoV-2 NP ( Figure 2D1-4) . In conclusion, pancreatic SARS- 19 CoV-2 infection, including that in the exocrine and endocrine cells, can occur in cats 20 infected with a high SARS-CoV-2 load. Figure S6A) . Notably, the expression of IL-20 6 increased by more than 100 times compared to that in control cats. Consistently, the Figure S6B-J) . These results indicated that cats 2 with SARS-CoV-2 infection experienced CS. 3 To confirm whether SARS-CoV-2 causes hyperglycemia in cats, we further performed a 4 vaccine protective experiment ( Figure 3A ). Six domestic kittens were immunized three 5 times with inactivated SARS-CoV-2. For control, three domestic kittens were immunized 6 with the culture medium of Vero cells under the same conditions. Following the three 7 rounds of immunization, we found that the serum neutralizing antibody titer in the 8 immunized cats was as high as 1:640 ( Figure 3B ). Subsequently, we challenged the 9 immunized and control cats with the virus at 2 × 10 7 TCID 50 /mL, with 1 mL administered 10 intratracheally and 1 mL administered intranasally. At 3, 5, and 7 dpi, the cats were 11 euthanized and the samples were collected. The RT-qPCR results showed a lower viral 12 load in immunized cats than in control cats (Supplementary Figure S7 ). In addition, the 13 pancreatic tissue of immunized cats tested negative for SARS-CoV-2 nucleic acid 14 (Supplementary Figure S6) . Similarly, the blood glucose levels of the challenged cats 15 were not altered significantly post immunization. However, the blood glucose levels of 16 the cats in the control group increased significantly ( Figure 3C ). In conclusion, SARS- ACE2 expression in beta cells [15] . However, we found ACE2 expression mainly in Glu+ 19 cells of the cat endocrine pancreas ( Figure 2C1-4) . Similar observations have also been 20 reported elsewhere. Tang and colleagues reported that SARS-CoV-2 viral RNAs, [21, 39] . Therefore, we speculated that the elevated 12 blood glucose content in SARS-CoV-2-infected cats may be a manifestation of metabolic 13 disorders caused by inflammation and CS. 14 However, to date, there is lack of information from detailed investigations of pancreatic 15 tissues from fatal COVID-19 cases. Therefore, whether there are pathological changes in In the current study, we found that SARS-CoV-2 RNA and protein are detectable in the 4 pancreatic tissues of cats after viral inoculation, and viral inoculation can induce an 5 increase in the blood glucose levels. Cats immunized with the inactivated virus were 6 resistant to subsequent infection and hyperglycemia. We believe that these data provide 7 important insights, shedding light on the possibility that pancreatic SARS-CoV-2 8 infection can lead to hyperglycemia. Our results also point to the utility of cats as model 9 animals for the study of the molecular mechanisms underlying blood glucose regulation 10 in individuals infected with SARS-CoV-2. 24 levels were measured at 3, 5, and 7 dpi. Each color bar represents the value from an 1 individual animal (IM3-1 and IM3-2: Immunized and SARS-CoV-2-infected cats at 3 2 dpi; IM5-1 and IM5-2: Immunized and SARS-CoV-2-infected cats at 5dpi; IM7-1 and 3 IM7-2: Immunized and SARS-CoV-2-infected cats at 7 dpi; no-IM3: Non-immunized 4 and SARS-CoV-2-infected cats at 3 dpi; no-IM5: Non-immunized and SARS-CoV-2- 5 infected cats at 5 dpi; no-IM7: Non-immunized and SARS-CoV-2-infected cats at 7 dpi;). 6 Dashed lines indicate the normal range of blood glucose (70-150 mg/dL). 

COVID-19, Hyperglycemia, and New-Onset Diabetes

Viral infiltration of pancreatic islets in patients with 12 COVID-19

SARS-CoV-2 infection induces beta cell transdifferentiation

A Human Pluripotent Stem Cell-based Platform to 16

Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

SARS-CoV-2 infects and replicates in cells of the 19 human endocrine and exocrine pancreas

Distinguishing the real from the hyperglycaemia: does COVID

COVID-19: consider cytokine storm syndromes and 5 immunosuppression

Susceptibility of ferrets, cats, dogs, and other domesticated 7 animals to SARS-coronavirus 2

A serological survey of SARS-CoV-2 in cat in Wuhan

The value of serology testing to manage SARS-11

CoV-2 infections

Detection of SARS-CoV-2 in a cat owned by a COVID-19-13 affected patient in Spain

SARS-CoV-2 in Quarantined Domestic Cats from COVID-19

Households or Close Contacts, Hong Kong

SARS-CoV-2 Natural Transmission from Human to 17

SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces 19 typical pneumonia

Cardiopulmonary bypass in the cat

Surgical closure of an atrial septal defect using 2 cardiopulmonary bypass in a cat

Surgical Treatment of Cor Triatriatum Sinister in a Cat 4

Under Cardiopulmonary Bypass

Validation of an enzyme-linked 6

immunosorbent assay for measurement of feline serum insulin

Homeostasis model assessment, serum insulin and their 8 relation to body fat in cats

SARS-CoV-2 and 10 pancreas: a potential pathological interaction?

Enteroviruses and T1D: Is It the Virus, the Genes or Both 12 which Cause T1D

SARS-CoV-2 infects human pancreatic beta cells and elicits 14 beta cell impairment

Deleterious Effects of SARS-CoV-2 Infection on 16

The protein expression profile 18 of ACE2 in human tissues

COVID-20 19 in Relation to Hyperglycemia and Diabetes Mellitus

COVID-19 and acute pancreatitis: examining the causality

Each color bar represents the value from an 11 individual animal (3-1 and 3-2: SARS-CoV-2-infected cats at 3 dpi; 5-1 and 5-2

Dashed 13 lines indicate the normal range of blood glucose (70-150 mg/dL). (D) Haematoxylin and 14 eosin-stained pancreatic tissue of cats challenged with SARS-CoV-2 at 5 dpi. Lesions 15 were absent in (a and b) the mock-infected and (c and d) challenged cats. Black bar, 200 16 μm. Green bar, 50 μm. (E) Immunohistochemical detection of SARS-CoV-2 NP antigen 17 at 5 dpi in the pancreatic islets of (a and b) mock-infected and (c and d) challenged cats

Acknowledgments.